Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model.

Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Abstract Text:

John D Morrey,Venkatraman Siddharthan,Aaron L Olsen,Hong Wang,Justin G Julander,Jeffery O Hall,Hua Li,Jeffrey L Nordstrom,Scott Koenig,Syd Johnson,Michael S Diamond,

A potent anti-West Nile virus (anti-WNV)-neutralizing humanized monoclonal antibody, hE16, was previously shown to improve the survival of WNV-infected hamsters when it was administered intraperitoneally (i.p.), even after the virus had infected neurons in the brain. In this study, we evaluated the therapeutic limit of hE16 for the treatment of WNV infection in hamsters by comparing single-dose peripheral (i.p.) therapy with direct administration into the pons through a convection-enhanced delivery (CED) system. At day 5 after infection, treatments with hE16 by the peripheral and the CED routes were equally effective at reducing morbidity and mortality. In contrast, at day 6 only the treatment by the CED route protected the hamsters from lethal infection. These experiments suggest that hE16 can directly control WNV infection in the central nervous system. In support of this, hE16 administered i.p. was detected in a time-dependent manner in the serum, cerebrospinal fluid (CSF), cerebral cortex, brain stem, and spinal cord in CSF. A linear relationship between the hE16 dose and the concentration in serum was observed, and maximal therapeutic activity occurred at doses of 0.32 mg/kg of body weight or higher, which produced serum hE16 concentrations of 1.3 microg/ml or higher. Overall, these data suggest that in hamsters hE16 can ameliorate neurological disease after significant viral replication has occurred, although there is a time window that limits therapeutic efficacy.

Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Publishing Authors By Initials

JD Morrey,V Siddharthan,AL Olsen,H Wang,JG Julander,JO Hall,H Li,JL Nordstrom,S Koenig,S Johnson,MS Diamond,

For similar viruses: rna viruses: flaviviridae: flavivirus: encephalitis viruses, japanese: west nile virus research abstracts see: viruses: rna viruses: flaviviridae: flavivirus: encephalitis viruses, japanese: west nile virus research

PUBMED ID PMID:

MEDLINE DATE:

Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Antimicrobial agents and chemotherapy

VOLUME: 51

Page Numbers: 2396-402

Journal Abbreviation: Antimicrob. Agents Chemother.

ISSN: 0066-4804

DAY: 23

MONTH: 04

YEAR: 2007

Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 315061

Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Keywords Mesh Terms:

KEYWORDS: West Nile virus

MESH TERMS: immunology

Chemical & Substance for Abstract: Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Information

Substance Name: Antiviral Agents

Registry Number: 0

Grant and Affiliation Information for Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model.

AFFILIATION: Institute for Antiviral Research, Animal, Dairy, and Veterinary Sciences Department, Utah State University, 4700 Old Main Hill, Logan, UT 84322-4700, USA. jmorrey@cc.usu.edu

Country: United States

AGENCY: United States NIAID

GRANT: U01-AI061373

ACRONYM: AI

MEDLINETA: Antimicrob Agents Chemother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model Related Publications

• A word to the wise: Tips for the first-time traveler.
• Ambient manganese exposure is negatively associated with human sperm motility and concentration.
• Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.
• Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells.
• Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis.
• Biotinylated photocleavable polyethylenimine: capture and triggered release of nucleic acids from solid supports.
• CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system.
• CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis.
• Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis.
• Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms.
• Consequences of variations in genes that affect dopamine in prefrontal cortex.
• Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model.
• Enhanced discrimination of single nucleotide polymorphism in genotyping by phosphorothioate proofreading allele-specific amplification.
• Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients.
• Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.
• In vivo beta-defensin gene expression in rat gingival epithelium in response to Actinobacillus actinomycetemcomitans infection.
• Interrelated and interdependent.
• Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease.
• Matrix protein microarrays for spatially and compositionally controlled microspot thrombosis under laminar flow.
• Methods for mapping protease specificity.
• Microinfusion of pituitary adenylate cyclase-activating polypeptide into the central nucleus of amygdala of the rat produces a shift from an active to passive mode of coping in the shock-probe fear/defensive burying test.
• Novel integrated paired emitter-detector diode (PEDD) as a miniaturized photometric detector in HPLC.
• Selenium and GPx-1 overexpression protect mammalian cells against UV-induced DNA damage.
• Synthesis and structure-activity relationships of a series of increasingly hydrophobic cationic steroid lipofection reagents.
• Systemic lupus erythematosus and Sjögren's syndrome.
• The molecular basis of antibody-mediated neutralization of West Nile virus.
• The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia.
• Thresholds in songbird occurrence in relation to landscape structure.
• Time and recruitment costs as currencies in manipulation studies on the costs of reproduction.
• West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H.